JFJudith Fraussen

Judith Fraussen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Judith Fraussen has a total of 109 co-authors. Here are the top co-authors by number of shared publications:

  • Veerle Somers

    Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Hasselt, Belgium

    22 shared publications
  • Piet Stinissen

    Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, 3590 Diepenbeek, Belgium

    8 shared publications
  • Raymond Hupperts

    Department of Neuroscience, School of Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands; Department of Neurology, Academic MS Center Limburg, Zuyderland Medisch Centrum, Sittard, the Netherlands

    8 shared publications
  • Bart Van Wijmeersch

    Biomedical Research Institute, Hasselt University and School of Life Sciences, Transnational University Limburg , 3500 Hasselt

    7 shared publications
  • Nele Claes

    Biomedical Research Institute, Hasselt University and School of Life Sciences, Transnational University Limburg , 3590 Diepenbeek

    6 shared publications
  • Mario Losen

    Department of Psychiatry and Neuropsychology Mental Health and Neuroscience Research Institute, Faculty of Health, Medicine and Life Sciences, Maastricht University Maastricht the Netherlands

    5 shared publications

Latest Publications

  • Open Access

    Enhanced MIF/CD74 axis activity shapes B cell functioning following traumatic spinal cord injury

    by Serina Rubio, Lien Beckers, Hanne Coenen, Charlotte C. M. van Laake-Geelen, Bart Depreitere, Sven Bamps, Erwin M. J. Cornips, Eveleen Buelens, Diedrik Peuskens, Jens Deckers, et al.

    A traumatic spinal cord injury (SCI) severely damages the nerve tissue of the spinal cord, often leading to long-term impairment of motor, sensory and auto


  • Open Access

    Peripheral Immune Remodeling After Spinal Cord Injury

    by Naomi Veeningen, Ana Laura Añé-Kourí, Astrid Pues, Serina Rubio, Judith Fraussen, Charalampia Ioannou, Dries S. Martens, Charlotte C.M. van Laake-Geelen, Jens Deckers, Erwin M.J. Cornips, et al.

    Spinal cord injury (SCI) is associated with severe immunologic changes, such as SCI-induced immune deficiency syndrome, which heightens susceptibility to infections. However, the immune components underlying this immune reorganization remain poorly defined. This study aimed to characterize immune remodeling in patients with SCI across different time points postinjury. High-dimensional flow cytometric profiling was performed on peripheral blood samples from patients with SCI in a cross-sectional observational study to assess immune changes at different postinjury time points. Patients in the subacute phase (22-67 days of postinjury [dpi]) and chronic phase (≥365 dpi) were compared with healthy, sex-matched, and age-matched controls. Alterations in the T-cell and natural killer (NK) cell compartments were observed, particularly in the subacute phase postinjury. Memory T cells and NK cells showed elevated expression of the NAD+ metabolizing enzyme CD38 and immune checkpoint molecules, cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1), indicating immune activation and possible exhaustion. Coexpression of CD38 and CTLA-4 on T cells was rare, suggesting distinct activation and inhibitory states. In chronic patients, we observed decreased frequencies of NK cells with no substantial changes in T cells and B cells. Notably, changes in CD38, CTLA-4, and PD-1 were no longer found in patients in the chronic phase. These findings reveal noteworthy changes in immune cell activation and exhaustion markers that may contribute to immune vulnerability after SCI, offering novel insights into potential therapeutic targets, such as NAD+ metabolism and immune checkpoint modulation.


  • Longitudinal Plasma Biomarker Profiles Predict Neurological Outcome in Traumatic Spinal Cord Injury

    by Judith Fraussen, Sjors G. J. G. In'T Veld, Charlotte C. M. van Laake‐Geelen, Bart Depreitere, Jens Deckers, Dieter Peuskens, Erwin M. J. Cornips, Sven Bamps, Charlotte E. Teunissen, Veerle Somers

    Objective: Traumatic spinal cord injury (SCI) is diagnosed by imaging and clinical scoring using the American Spinal Injury Association Impairment Scale (AIS). These methods have limited value for prognosis. Here, the prognostic value of plasma neurofilament‐light (NfL), glial fibrillary acidic protein (GFAP), and contactin‐1 (CNTN‐1) was analyzed.Methods: Biomarker levels were determined in the plasma of traumatic SCI patients (n = 37) and healthy controls (n = 22). SCI samples (n = 112) were collected at different time points from 0 to 4 days to 18 weeks post‐injury. NfL and GFAP were measured by single molecule array (Simoa) technology, CNTN‐1 by Luminex. Baseline and outcome AIS and motor scores were collected as a measure of injury severity.Results: NfL, GFAP, and CNTN‐1 showed different kinetics in SCI patients over time. Baseline biomarker levels could identify AIS‐A SCI patients (NfL + GFAP) and discriminate between patients with a motor score change <5 and those with a change ≥5 (NfL + GFAP+CNTN‐1). Longitudinally, NfL could identify AIS‐A patients up to 12 weeks post‐SCI and discriminate between patients with a motor score change <5 and those with a change ≥5 up to 18 weeks post‐SCI. Further, baseline biomarker levels positively (NfL + GFAP) or negatively (CNTN‐1) correlated with outcome injury severity and together could accurately predict AIS conversion (AUC 0.863) and motor score change (AUC 0.857). This predictive ability was maintained in subacute/chronic SCI stages.Interpretation: In conclusion, plasma NfL, GFAP, and CNTN‐1 are potential prognostic biomarkers in SCI. This is important for patient stratification in clinical trials, prediction of neurological outcome and informed decision‐making in SCI treatment and rehabilitation. ANN NEUROL 2025;97:1180–1189


  • Open Access

    Peripheral immune reactions following human traumatic spinal cord injury: the interplay of immune activation and suppression

    by Hanne Coenen, Veerle Somers, Judith Fraussen

    Traumatic spinal cord injury (SCI) damages the nerve tissue of the spinal cord, resulting in loss of motor and/or sensory functions at and below the injury level. SCI provokes a long-lasting immune response that extends beyond the spinal cord and induces changes in the composition and function of the peripheral immune system. Seemingly contradictory findings have been observed, as both systemic immune activation, including inflammation and autoimmunity, and immune suppression have been reported. Differences in the levels and functions of various cell types and components of both the innate and adaptive immune system supporting these changes have been described at (sub)acute and chronic stages post-injury. Further research is needed for a more comprehensive understanding of the peripheral immune reactions following SCI, their possible correlations with clinical characteristics, and how these immune responses could be targeted to facilitate the therapeutic management of SCI. In this review, we provide an overview of the current literature discussing changes in the peripheral immune system and their occurrence over time following a traumatic SCI.


  • Open Access

    Fibroblast-like synoviocyte targeting antibodies are associated with failure to reach early and sustained remission or low disease activity after first-line therapy in rheumatoid arthritis

    by Patrick Vandormael, Sukayna Fadlallah, Pieter Ruytinx, Astrid Pues, Ellen Sleurs, Jori Liesenborgs, Johan Joly, Anouk Agten, Frank Vandenabeele, Judith Fraussen, et al.

    Objective To discover antibody biomarkers that can predict a lack of response to first-line therapy in rheumatoid arthritis (RA) patients. Methods Two RA cDNA phage display libraries were screened for novel antibodies in baseline RA sera from the Care in early RA (CareRA) trial, differentiating between patients who did or did not reach remission after first-line therapy (n=20 each). Antibody reactivity to identified University Hasselt (UH)-RA antigens was validated in baseline samples from 136 additional CareRA participants. The novel antibodies’ potential to predict failure to reach remission or low disease activity (LDA), according to the Disease Activity Score 28-joint C-reactive protein/erythrocyte sedimentation rate (DAS28CRP/ESR) and Clinical/Simplified Disease Activity Index (CDAI/SDAI), was studied by multivariate analyses. The presence of the antibody targets in RA synovial tissue and the fibroblast-like synoviocyte (FLS) cell line SW982 was determined by immunofluorescence. Results We identified antibodies to 41 novel antigens. Antibodies against any of three antigens, UH-RA.305/318/329, discriminated between RA patients not reaching week (w)8 DAS28CRP remission and those that did (36% vs 13%,p=0.0031). In all patients, anti-UH-RA.305/318/329 antibody reactivity was associated with failure to reach week 8 DAS28CRP and DAS28ESR remission (OR 3.63,p=0.0031; OR 2.92,p=0.016; respectively), SDAI/CDAI sustained remission (OR 5.59,p=0.039 for both) and DAS28CRP and DAS28ESR sustained LDA (OR 3.7,p=0.009; OR 2.76,p=0.042; respectively). In rheumatoid factor/anti-citrullinated protein antibody (RF/ACPA) seronegative patients, these antibodies were strongly associated with failure to achieve week 8 DAS28CRP remission (OR 17.3,p=0.0029). Anti-UH-RA.305/329 antibodies were shown to target FLS in RA synovial tissue and SW982 cells. Conclusion We identified three antibody biomarkers that are associated with failure to achieve remission/LDA after first-line RA therapy.


  • Open Access

    Editorial: New Insights Into B Cell Subsets in Health and Disease

    by Veerle Somers, Deborah K. Dunn-Walters, Mirjam van der Burg, Judith Fraussen

    Editorial: New Insights Into B Cell Subsets in Health and Disease


  • Phenotypic and Ig Repertoire Analyses Indicate a Common Origin of IgD−CD27− Double Negative B Cells in Healthy Individuals and Multiple Sclerosis Patients

    by Judith Fraussen, Susanna Marquez, Kazushiro Takata, Lien Beckers, Gwendoline Montes Diaz, Chrysoula Zografou, Bart Van Wijmeersch, Luisa M. Villar, Kevin C. O’connor, Steven H. Kleinstein, et al.

    IgD−CD27− double negative (DN) B cells with proinflammatory characteristics are abnormally elevated in a proportion of multiple sclerosis (MS) patients. In this study, the origin and selection characteristics of DN B cells were studied in MS patients and healthy controls (HC). Expression of developmental markers on peripheral blood DN, IgD−CD27+ class-switched memory (CSM) and IgD+CD27− naive B cells of HC (n = 48) and MS patients (n = 96) was determined by flow cytometry. High-throughput adaptive immune receptor repertoire sequencing was performed on peripheral blood DN and CSM B cells of HC and MS patients (n = 3 each). DN B cells from HC and MS patients showed similar phenotypic and Ig repertoire characteristics. Phenotypic analysis indicated a mature state of DN B cells by low CD5, CD10, and CD38 expression. However, the frequency of CD95+ and IgA+ cells was lower in DN versus CSM B cells. DN B cells are Ag experienced, as shown by somatic hypermutation of their Ig genes in adaptive immune receptor repertoire sequencing, although they showed a lower mutation load than CSM B cells. Shared clones were found between DN and CSM B cells, although >95% of the clones were unique to each population, and differences in V(D)J usage and CDR3 physicochemical properties were found. Thus, DN B cells arise in HC and MS patients via a common developmental pathway that is probably linked to immune aging. However, DN and CSM B cells develop through unique differentiation pathways, with most DN B cells representing an earlier maturation state. Key Points DN B cells are abnormally elevated in MS patients but have the same origin as in HC. DN B cells resemble CSM B cells but appear to be at an earlier maturation state. DN and CSM B cells undergo unique differentiation pathways.